SERPINE1 and COVID-19: A series of clinical studies were therefore conducted in Japan to evaluate the efficacy and safety of PAI-1 inhibitors for COVID-19 pneumonia, i.e., an open-label, early phase II clinical trial and a randomized, double-blind, placebo-controlled, late phase II clinical trial in COVID-19 patients with mild to moderate pneumonia.